Defendant
1 case as defendant.
InnerCap Technologies, Inc. (styled "INNERCAP Technologies") is a privately held drug-delivery technology company headquartered at 9216 Palm River Road, Tampa, Florida, and founded in 2003. Longtime President/CEO is Fred Miller. Business directories list headcount in the 1–10 employee range; no venture funding has been reported, and no reliable public revenue figure exists — third-party aggregator estimates should not be treated as verified. The company is not publicly traded and reports no parent or affiliate.
Products / operations. InnerCap develops a patented multi-phase, multi-compartment "capsule-in-capsule" oral delivery system (marketed as NOVACAP technology). A smaller inner capsule sits inside a larger outer capsule, allowing incompatible or physically dissimilar actives — e.g., an oil or semi-solid in the outer chamber and a powder, pellet, or lyophilized solid inside — to be co-administered in one dosage form with immediate, delayed, or staged release. Target applications are Rx and OTC pharmaceuticals, medical foods, and nutraceutical combination products. Its disclosed U.S. patents include 7,670,612; 8,361,497; 9,241,911; and 9,539,216. The company functions primarily as a small technology/IP licensor rather than a large-scale manufacturer.
Litigation posture. Primarily a plaintiff asserting its own internally developed portfolio, not an acquired one: 4 tracked plaintiff cases against 2 defendant-side appearances. The recent suits all assert the 2010 '612 patent (claim 33) against capsule-in-capsule supplement products sold by retailers and brands. This is not an Eastern District of Texas pattern; filings cluster in the District of Delaware (Judge Jennifer L. Hall) and the District of Minnesota.
Notable cases. In 2026 InnerCap sued Walmart (D. Del., Apr. 27), Target over its Ritual line (D. Minn., Apr. 30), Natals, Inc. d/b/a Ritual (D. Del., Jul. 8), and Nouri Life, Inc. (D. Del., Jul. 24). The Walmart case was stayed Aug. 24, 2026, pending the Natals and Nouri Life actions; Natals/Ritual separately filed a declaratory-judgment action against InnerCap in the Central District of California. Historically, InnerCap was the patent owner targeted in a 2013 PTAB inter partes review petitioned by Capsugel Belgium NV (IPR2013-00331), a capsule-industry competitor.
Declaratory judgment action filed by Natals, Inc. d/b/a Ritual against InnerCap Technologies under 28 U.S.C. § 2201. A Notice of Pendency of Other Actions was filed, and it is the mirror DJ action to InnerCap's Delaware suit against Natals.